Report: Drug Discovery Industry Must Embrace Open Source Innovation to Speed Process, Boost Bottom Lines

To meet the challenges of research and development, the pharmaceutical industry must adopt more open source innovation—a concept that has been used for nearly three decades by the information technology sector—to promote innovation in the drug discovery process and boost bottom lines, according to a new report by Frost & Sullivan.